Choroidal neovascularization (CNV) with chorioretinal atrophy is the most common cause of poor vision in patients with pathologic myopia.1 In India, refractive errors are a major cause of treatable blindness. Population surveys in southern India have shown prevalence of high myopia to be 4.32-4.54%. Photodynamic therapy (PDT) for choroidal neovascularization (CNV) caused by pathologic myopia is beneficial.

Aims: To report the 24 months outcome of PDT with verteporfin for subfoveal CNV caused by pathologic myopia in Indian eyes

Settings and Design: Prospective case series

Materials and Methods: Review of prospectively collected data of Indian patients with pathologic myopia and subfoveal CNV treated with verteporfin therapy between 2001 and 2005 using standard regimen for PDT.

Statistical Analysis Used: Wilcoxon signed rank test was used to see the difference in the mean letter acuity at intervals compared to baseline. Kaplan Meier Survival analysis was done to estimate the success rate of verteporfin therapy for CNV caused by pathologic myopia.

Results: Fifteen patients (15 eyes) treated with standard fluence PDT and who had completed 24 months follow-up were analyzed. The mean spherical equivalent was -13.36 ± 5.88 diopter. Five out of 15 eyes in six months, three out of 15 eyes at 12 months and four eyes out of 15 at 24 months had improved vision by > 10 letters. The mean number of treatment session was 2.2 in two years.

Conclusions: PDT with verteporfin for subfoveal CNV caused by pathologic myopia in Indian eyes is effective.

Key words: Choroidal neovascularization, pathologic myopia, photodynamic therapy, subfoveal, verteporfin

Indian J Ophthalmol: 2008;56:465-8
in south India.

**Materials and Methods**

We reviewed the prospectively collected data of patients receiving PDT with verteporfin for subfoveal CNV secondary to pathologic myopia during the period from May 2001 to June 2005. All patients underwent ocular examination in each visit which included:

- ETDRS letter acuity (best corrected) at 4 meters
- Dilated slit-lamp biomicroscopy
- Dilated fundus examination (+90 D and +20 D)
- Color fundus photograph
- Fundus fluorescein angiography (FFA)

The inclusion and exclusion criteria and method of treatment were similar as published earlier. Briefly, the inclusion criteria were best corrected visual acuity ≥ 20/200; myopia ≥ 6 diopter; fundus changes characteristic of chorioretinal atrophy, lacquer cracks and posterior staphyloma and age ≥ 18 years. The exclusion criteria were history of previous macular laser, intraocular surgery in the last three months and other ocular disorders possibly causing CNV (viz. Angioid streaks and age-related macular degeneration).

Patients who completed at least 24 months follow-up were included in the study. The follow-up schedule was every three months. All the tests were repeated on each follow-up visit.

The primary outcome measure was visual outcome and secondary outcome was the number of retreatments. Improvement was defined as a gain of ≥ 10 ETDRS letters, deterioration as a loss of > 10 ETDRS letters and stabilization as < 10 letters gain or loss. Success was defined as improvement or stabilization of vision.

Wilcoxon signed rank test was used to see the difference in the mean letter acuity at intervals compared to the baseline. Kaplan Meier Survival analysis was done to estimate the success rate of verteporfin therapy for CNV caused by pathologic myopia.

Photodynamic therapy with verteporfin for CNV caused by pathologic myopia and the study protocol had been approved by the ethics committee of the institute in 2001.

**Results**

The age range of these 15 patients (eight male and seven female) was from 28 to 57 years (41 ± 10.02). Right eye was affected in eight patients. The mean spherical equivalent was -13.46 ± 5.88 diopter (range: -6.0 to -25.0 diopter). All patients completed at least 24 months follow-up.

At the baseline, four out of 15 eyes had visual acuity (VA) ≥ 20/40, six eyes out of 15 had between 20/50 and 20/80; and five eyes out of 15 had ≥ 20/200. At 24 months, four eyes out of 15 each had VA ≥ 20/40 and between 20/50 and 20/80 respectively, and seven eyes out of 15 had ≥ 20/200 [Figure 1].

Figure 2 shows the trend of mean letter acuity over a period of 24 months. At six months, there was significant improvement in mean letter acuity (33.8 ± 12.4) from baseline (27.4 ± 15.2) (P=0.02), but there was no difference at 12 (P=0.3), 18 (P=0.9) and 24 months (P=0.95). Compared to improvement in letter acuity in the first six months, there was reduction in mean letter acuity at 18 (28.1 ± 14.8) (P=0.02) and 24 months (27.3 ± 14.3) (P=0.05).

Five out of 15 eyes at six months, three out of 15 eyes at 12 and 18 months, and four out of 15 at 24 months follow-up gained ≥ 10 letters [Figure 3].
Survival analysis showed a success rate of 100% at six months, 93.3% (SE=0.064) at 12 months and 73.3% (SE=0.114) at 24 months.

The mean number of PDT treatment session was 2.2 (Range: 1-5, Mode: 2). It was 2.06 (range: 1-5) in the first year and 0.13 (range: 0-2) in the second year. Retinal pigment epithelial collateral change was seen in five out of 15 eyes.

Discussion

Presence of subfoveal CNV is one of the major causes of decreased vision in pathologic myopia (5-10%) besides progression of myopic macular chorioretinal atrophy. Moreover, high myopia is common in the Asian population, compared to the Caucasian population (2-4%). The VIP Study has shown the beneficial effect of PDT and demonstrated that verteporfin therapy improves the chance of stabilization (< 8 letters loss) or causes improvement of vision compared to either natural history or placebo at least at 24 months follow up.

The present study has demonstrated that verteporfin therapy is beneficial in stabilization of vision at 24 months. Significant improvement of vision was seen at six months (P=0.02) from baseline but did not maintain till 24 months. Actually, a drop in visual acuity (VA) was seen after 12 months and the VA at 24 months was not significantly different from the baseline visual acuity. We have reported initial improvement of vision with verteporfin therapy in the first six months in neovascular age-related macular degeneration. Even though the mean visual acuity change at 24 months was not statistically significant, at least four out of 15 of eyes gained ≥ 10 letters and there was a success rate of 73.3% (S.E: 0.114) at the end of follow-up. The 24 months’ experience of a case series of 22 Asian Chinese eyes have also shown no statistical difference in mean best corrected visual acuity (P=0.5). Initial improvement of vision noted in the first three months did not sustain for two years. We had shown in our earlier report that eight of nine eyes had unchanged vision at the end of one year following PDT. The current report suggests that the trend is nearly similar and PDT stabilizes the vision in high myopic eyes with CNV.

In our study cohort, the mean number of treatment was 2.2 in 24 months and interestingly, 93.6% of the treatment (2.06) was required in the first year itself. This was almost similar to the report by Lam et al., (mean treatment rate of 2.3) in 24 months. This may suggest that chances of recurrence of CNV needing treatment or requiring retreatment in the second year are minimal. The VIP study showed a higher mean treatment rate of 5.1 at 24 months in Caucasian eyes.

Though PDT is helpful in stabilizing vision in pathologic myopia with CNV, currently there are other alternatives and options which were not available at the time of the study duration. While the anti-VEGF therapy has largely taken over as the primary treatment mode in subfoveal CNV, the role of PDT is still considered and tried the world over. Since the mechanism of actions is different, there could be a role for both PDT and anti-VEGF therapy in the future. Our study shows a limited role of PDT, and possibly today, combined with the anti-VEGF therapy could be more beneficial than PDT alone as shown in past.

Thus, this study shows that verteporfin therapy in subfoveal CNV caused by pathologic myopia is equally effective in Indian eyes and compares well with the study in Asian Chinese eyes from Hong Kong. It may be possible that some ethnic variation may exist even amongst the Asian population. The ethnic variation between Asian and Caucasian population is not clearly known. This disparity may be due to more pigments in retinal pigmented epithelium providing a possible protective effect.

References

1. Avila MF, Weiter JJ, Jalkh AE, Trempe CL, Schepens CL. Natural history of choroidal neovascularisation in degenerative myopia. Ophthalmology 1984;91:1573-8.
2. Thulasiraj RD, Nirmalan PK, Ramakrishnan R, Krishnadas R, Manemakalai TK, Baburajan NP, et al. Blindness and vision impairment in a rural South Indian population: The Aravind Comprehensive Survey. Ophthalmology 2003;110:1491-8.
3. Dandon A, Dandon L, Srinivas M, Giridhar P, McCarty CA, Rao GN. Population based assessment of refractive error in India: the Andhra Pradesh Eye Disease Study. Clin Exp Ophthalmol 2002;30:84-93.
4. Raju P, Ramesh SV, Arvind H, George R, Baskaran M, Paul PG, et al. Prevalence of refractive errors in a rural southern Indian population. Invest Ophthalmol Vis Sci 2004;45:4268-72.
5. Wong TY, Foster PJ, Hee J, Ng TP, Tielsch JM, Chew SJ et al. Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Invest Ophthalmol Vis Sci 2000;41:2486-94.
6. Sperduto RD, Seigel D, Roberts J, Rowland M. Prevalence of myopia in the United States. Arch Ophthalmol 1983;101:405-7.
7. Curtin B. The myopias: Basic science and clinical management. Philadelphia: Harper and Row; 1983. p. 7-10.
8. Zhou C. Mechanisms of tumour necrosis induced by photodynamic therapy. J Photochem Photobiol B 1989;3:299-318.
9. Cohen SY, Bulik A, Dubois L, Quentel G. Photodynamic therapy for juxtafoveal choroidal neovascularisation in myopic eyes. Am J Ophthalmol 2003;136:371-4.
10. Bandello F, Lanzetta P, Battaglia Parodi M, Ranam Poginuz D, Saviano S, Ravalico G. Photodynamic therapy of subfoveal recurrences after laser photoacogulation of extrafoveal choroidal neovascularization in pathologic myopia. Graefe's Arch Clin Exp Ophthalmol 2003;241:567-70.
11. Lams DS, Chan WM, Liu DT, Fan DS, Lai WW, Chang KK. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: A prospective series of 1 and 2 year follow up. Br J Ophthalmol 2004;88:1315-9.
12. Varano M, Parisi V, Tedeschi M, Sciamama M, Gallinaros G, Capaldo N, et al. Macular function after photodynamic therapy in myopic maculopathy: Psychophysical and electrophysiological evaluation. Invest Ophthalmol Vis Sci 2003;46:1453-62.
13. Tholen AM, Bernaasconi PP, Fierz AB, Messmer EP. Reading ability after photodynamic therapy for age related macular degeneration and high myopia. Ophthalmologie 2003;100:29-32.
14. Ruiz-Moreno JM, Montero JA. Visual acuity results after argon green laser photoacogulation of juxtafoveal choroidal neovascularization in highly myopic eyes: Long term results. Eur J Ophthalmol 2002;12:117-22.
15. Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 2001;85:1041-3.
16. Tabandeh H, Flynn HW Jr, Scott IU, Lewis ML, Rosenfeld PJ, Rodriguez F, et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularisation. Ophthalmology 1999;106:2063-7.
17. Ohno-Matsui K, Yoshida T. Myopic choroidal neovascularisation: Natural course and treatment. Curr Opin Ophthalmol 2004;15:197-202.

18. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, et al. Verteportin therapy of subfoveal choroidal neovascularisation in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003;110:667-73.

19. Ruiz-Moreno, Montero JO. Subretinal fibrosis after photodynamic therapy of subfoveal choroidal neovascular membrane in highly myopic eyes. Br J Ophthalmol 2003;87:856-9.

20. Sakaquchi H, Ikuno Y, Gwui F, Kamei M, Sawa M, Tsujikawa M, et al. Intravitreal injection of Bevacizumab for choroidal neovascularisation caused by pathologic myopia. Br J Ophthalmol 2006 Aug 16 (Epub ahead of print).

21. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 2007;91:157-60.

22. Marticorena J, Gomez-Ulla F, Fernandez M, Pazos B, Rodriguez-cid MJ, Sanchez-Salorio M. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularisation. Am J Ophthalmol 2006;142:335-7.

23. Hussain N, Das T, Vashist U, Sumasri K. Verteportin therapy for myopic choroidal neovascularisation in Indian eyes (one year results). Indian J Ophthalmol 2004;52:227-31.

24. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, et al. Myopic choroidal neovascularisation: Ten year follow up. Ophthalmology 2003;110:1297–305.

25. Chan WM, Ohji M, Lai TY, Liu DT, Tano Y, Lam DS. Choroidal neovascularisation in pathological myopia: An update in management. Br J Ophthalmol 2005;89:1522-8.

26. Hussain N, Das T, Khanna R, Sumasri K, Mohan Ram LS. Verteportin therapy for Neovascular Age related macular degeneration in Indian eyes. Ipn J Ophthalmol 2005;50:524-8.

27. Hussain N, Das T, Rawal H, Kallukuri SB, Mohan Ram LS, Khanna R. Combination therapy of intravitreal triamcinolone and photodynamic therapy for neovascular age related macular degeneration. Indian J Ophthalmol 2006;54:247-50.

Source of Support: Nil, Conflict of Interest: None declared.